Imcyse

Avenue du Pré-Aily 14

4031 Liège Angleur

BE

Imcyse

Foundation date

10-08-2010

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Imcyse develops active targeted immune therapies (ImotopesÔ) that locally inhibit the immune cells involved in the destruction of the diseased organ. The targeted approach and memory effect of the Imcyse technology help to prevent and cure diseases with no current therapeutic alternative, caused by disruptions of the immune system without impairing the patient’s immune defences. 

Upcoming events

Latest news

  • Mithra announces topline results for COVID-19 Phase II Study

    1 day ago

  • Biocartis announces restart of its high-throughput cartridge manufacturing line

    Thursday September 23rd 2021

  • Rewind Therapeutics appoints Anja Harmeier, PhD, MBA, as Chief Executive Officer

    Wednesday September 22nd 2021